hotspot -WSS

hotspot

author：comprehensive 2025-10-02 10:46:01 - browse：742

Illustration of a red heart. -- health coverage from STAT — Adobe

Novo Nordisk’s obesity drug Wegovy cut the risk of major heart complications by 20% in a closely watched trial, results that could streamline insurance coverage and spur even greater demand for the highly popular therapy.

The milestone Select trial of about 17,500 patients is the first to show that an obesity medication leads to long-term cardiovascular benefits. The company reported only the topline figure in a press release Tuesday, and did not break out the reductions it said were seen in heart attacks, strokes, and cardiovascular deaths — the combined components of the study’s primary outcome. It said all three contributed to the decrease in cardiovascular events in the group that received Wegovy compared with participants given a placebo.

The 20% reduction was greater than many observers were expecting. In a research note Tuesday, Jefferies analysts called the results a “best case” outcome. “If they play baseball in Denmark,” Barclays analyst Emily Field wrote in a note, “Wegovy just hit a home run.”

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Medicare details structure of new drug price negotiation program
Next article： Readout Newsletter: The latest on Novo Nordisk, Alnylam, Apogee

WSS

He's 19 months old and has one of the world’s rarest diseases

State of the Union pitch: Bigger Medicare drug price negotiations

Readout Newsletter: The latest on Novo Nordisk, Alnylam, Apogee

He's 19 months old and has one of the world’s rarest diseases

Stem cell biologist probes earliest stages of human development

Indiana Supreme Court upholds abortion ban, says state constitution gives only limited protections

focus

hotspot

knowledge

Novavax promises a turnaround & Lilly roils the obesity market

Affirmative action in medical school literally saved lives

Indiana Supreme Court upholds abortion ban, says state constitution gives only limited protections

Readout Newsletter: BridgeBio, Akero, and human embryo models

Virginia high school admissions case could be legal follow

DIEP, the 'gold standard' of breast reconstruction, is under threat

Anesthesiologist group: stop taking Ozempic before surgery

Readout Newsletter: The latest on Novo Nordisk, Alnylam, Apogee

Medical records are filled with copy

After affirmative action ruling, medical educators look to 'holistic review'

leisure time

Florida health officials providing scant details on measles cases

Streamlined flu vaccines recommended by FDA advisory panel

Ozempic has benefits for kidney disease as well as diabetes

State of the Union pitch: Bigger Medicare drug price negotiations

Change Healthcare: What is it, why does its cyberattack matter?

Readout Newsletter: The latest on Novo Nordisk, Alnylam, Apogee

leisure time

entertainment

hotspot

leisure time